Helus Pharma Eyes Key Milestones Amid Rising Clinical Trial Costs

BOSTON and TORONTO – February 13, 2026 – Helus Pharma finds itself at a pivotal crossroads, balancing a robust financial position with the escalating costs of late-stage drug development, according to its third-quarter fiscal 2026 results. The clinical-stage pharmaceutical company reported a healthy cash position of US$195.1 million but also a significantly widened net loss of US$42.7 million as it pushes its novel mental health therapies toward critical data readouts.

Investors and patients are keenly watching for the first of these major catalysts: topline data from a Phase 2 study of its drug candidate HLP004 for generalized anxiety disorder (GAD), expected before the end of this quarter. The announcement underscores a period of intense activity for the company, which recently rebranded from Cybin Inc. and appointed a new CEO to steer its transition from a research entity to a potential commercial powerhouse in the mental health space.

“We are advancing a differentiated, multi-asset neuroscience portfolio with programs spanning multiple stages of development and indications,” said Michael Cola, who recently took the helm as Chief Executive Officer. “With a strong balance sheet, continued progress across our HLP003 Phase 3 and HLP004 Phase 2 programs, and a focus on scalable, repeatable clinical architectures, Helus Pharma is well positioned as we move toward upcoming clinical catalysts and long-term value creation.”

The Looming Anxiety Treatment Catalyst

The most immediate test for Helus Pharma’s strategy will come within weeks. The company is poised to release topline results from its Phase 2 trial of HLP004, a proprietary deuterated novel serotonergic agonist (NSA) designed to treat generalized anxiety disorder. This data will provide the first major glimpse into the drug's efficacy and safety in a GAD population, a condition affecting millions worldwide with significant unmet needs.

Confidence in HLP004 is supported by earlier exploratory data from a related, non-deuterated compound which demonstrated significant anxiety reduction in patients with major depression. This upcoming readout will be crucial in determining the path forward for HLP004, potentially positioning it as a competitor in a space that is seeing renewed innovation. For instance, companies like MindMed are also advancing psychedelic-inspired therapies like MM120 for GAD, signaling a broader industry shift away from traditional daily medications toward novel, potentially rapid-acting treatments. A positive result for HLP004 could validate Helus Pharma’s scientific platform and add a second major asset to its late-stage pipeline.

Advancing a Breakthrough Depression Therapy

While HLP004 approaches its moment of truth, the company’s flagship program, HLP003, continues its advance through a large-scale Phase 3 program for the adjunctive treatment of major depressive disorder (MDD). HLP003 has already received a significant vote of confidence from the U.S. Food and Drug Administration (FDA) in the form of a Breakthrough Therapy Designation. This status is reserved for drugs that have shown substantial improvement over available therapies in early clinical evidence and is designed to expedite development and review.

The designation was granted based on impressive Phase 2 data where HLP003 demonstrated rapid and durable improvements in depression symptoms. Patients in that study showed a nearly 23-point mean reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) score, with 71% of participants achieving remission. The ongoing Phase 3 program, known as PARADIGM, consists of two pivotal studies, APPROACH™ and EMBRACE™, with initial topline data from the APPROACH study anticipated in the fourth quarter of 2026. An associated long-term extension study is also underway to gather crucial safety and durability data, which will be vital for regulatory submission and commercial positioning.

A Strategic Overhaul for Commercial Ambitions

Underpinning these clinical efforts is a significant corporate transformation aimed at preparing Helus Pharma for a potential product launch. The recent appointment of Michael Cola as CEO is a cornerstone of this strategy. Cola brings a formidable track record in commercializing major central nervous system therapies, most notably his role in building Vyvanse into a multi-billion-dollar franchise during his time as President of Shire's Specialty Pharmaceutical business. His experience at companies like AstraZeneca and Sage Therapeutics is seen as critical for navigating the complex transition from clinical development to market.

This leadership change coincides with the company’s rebranding from Cybin Inc. to Helus Pharma, a move intended to reflect its evolution toward a commercial-stage pharmaceutical entity. The company's reframed focus is on engineered serotonergic agonists designed for controlled pharmacokinetics and scalability, moving beyond its earlier identity which was more closely associated with foundational psychedelic research.

The Financial Realities of Late-Stage Development

The company’s ambitious clinical programs are reflected in its latest financial report. While the US$195.1 million in cash provides a solid runway, the costs of development are rising sharply. Cash-based operating expenses climbed to US$36.7 million for the quarter, up from US$20 million in the same period last year. Consequently, the net loss ballooned to US$42.7 million from US$7.5 million year-over-year.

This increased cash burn is a direct result of advancing the large and costly Phase 3 MDD program and the Phase 2 GAD trial. Based on its current spending, the company’s cash reserves are projected to last approximately 16 to 18 months. This timeline provides a sufficient financial cushion to see it through its upcoming HLP004 data readout and well into the execution of the HLP003 Phase 3 trials, whose own data release in late 2026 will be another defining moment for the company's future.

Building a Moat with Intellectual Property

To secure its long-term market position, Helus Pharma has been aggressively building a robust intellectual property portfolio. The company reports having over 350 patent applications filed and more than 100 patents granted globally. This strategy is designed to create a defensible “blocking position” around its key assets.

Specifically, both HLP003 and HLP004 are protected by composition of matter patents and other claims covering manufacturing, formulation, and methods of use. This intellectual property is expected to provide protection until at least 2041, offering a potential 15-year window of market exclusivity post-approval. This extensive patent estate is a critical asset, providing strategic flexibility and reinforcing the company's potential for long-term value creation as it works to deliver a new generation of treatments for complex mental health conditions.